Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Axsome Therapeutics: Sunosi met the primary endpoint in the SHARP study » 06:35
10/03/22
10/03
06:35
10/03/22
06:35
AXSM

Axsome Therapeutics

$44.62 /

+0.45 (+1.02%)

Axsome Therapeutics…

Axsome Therapeutics announced that Sunosi met the primary endpoint in the SHARP study and significantly improved cognitive function, measured using the Digit Symbol Substitution Test subtest of the Repeatable Battery for the Assessment of Neuropsychological Status, as compared to placebo in cognitively impaired patients with excessive daytime sleepiness associated with obstructive sleep apnea. Superiority of Sunosi as compared to placebo was further demonstrated using patient-reported measures of cognitive function. In the study, Sunosi replicated previous findings by significantly reducing EDS symptoms as compared to placebo. On the study's primary endpoint, Sunosi demonstrated statistically significant improvement in cognitive function compared to placebo as assessed by the change from baseline on the DSST RBANS, with an effect size of 0.36. The DSST RBANS is an objective neuropsychological test that assesses executive function, processing speed and attention. Statistically significant improvement in cognitive function with Sunosi treatment was also demonstrated using the British Columbia Cognitive Complaints Inventory overall score compared to placebo, with an effect size of 0.43. The BC-CCI is a patient-reported test that assesses domains of memory, concentration, trouble expressing thoughts, word finding, and problem solving. Sunosi significantly improved EDS symptoms compared to placebo, as measured by the Epworth Sleepiness Scale. The improvement on the ESS with Sunosi treatment was approximately twice that observed with placebo, with an effect size of 0.50. The most commonly reported adverse events with Sunosi treatment (incidence greater than or equal to3%) were nausea (6.9%) and anxiety (3.4%). The study completion rate was 96.7% for patients randomized to each treatment sequence.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$44.62 /

+0.45 (+1.02%)

AXSM Axsome Therapeutics
$44.62 /

+0.45 (+1.02%)

09/30/22 Jefferies
Axsome Therapeutics price target lowered to $90 from $92 at Jefferies
09/28/22 Mizuho
Mizuho says Biogen data will serve as catalyst for these stocks
09/07/22 Mizuho
Axsome Therapeutics assumed with a Buy at Mizuho
08/23/22 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $180 at H.C. Wainwright
AXSM Axsome Therapeutics
$44.62 /

+0.45 (+1.02%)

AXSM Axsome Therapeutics
$44.62 /

+0.45 (+1.02%)

AXSM Axsome Therapeutics
$44.62 /

+0.45 (+1.02%)

Friday
Recommendations
Axsome Therapeutics price target lowered to $90 from $92 at Jefferies » 09:18
09/30/22
09/30
09:18
09/30/22
09:18
AXSM

Axsome Therapeutics

$44.16 /

-2.57 (-5.50%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton lowered the firm's price target on Axsome Therapeutics to $90 from $92 and keeps a Buy rating on the shares after the company said following a Type A Meeting with the FDA that it will now resubmit its NDA for AXS-07 for the acute treatment of migraine in Q3 of 2023. The six month review from guidance leads him to push back a migraine launch to the second half of 2024 from the second half of 2023 previously and this delay reduces his target , but Howerton contends that this opportunity for '07 is "dwarfed by the ongoing MDD launch."

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$44.16 /

-2.57 (-5.50%)

AXSM Axsome Therapeutics
$44.16 /

-2.57 (-5.50%)

09/28/22 Mizuho
Mizuho says Biogen data will serve as catalyst for these stocks
09/07/22 Mizuho
Axsome Therapeutics assumed with a Buy at Mizuho
08/23/22 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $180 at H.C. Wainwright
08/22/22 SVB Securities
Axsome Therapeutics price target raised to $75 from $50 at SVB Securities
AXSM Axsome Therapeutics
$44.16 /

-2.57 (-5.50%)

AXSM Axsome Therapeutics
$44.16 /

-2.57 (-5.50%)

AXSM Axsome Therapeutics
$44.16 /

-2.57 (-5.50%)

Thursday
Hot Stocks
Axsome to resubmit AXS-07 NDA based on FDA Type A meeting » 07:29
09/29/22
09/29
07:29
09/29/22
07:29
AXSM

Axsome Therapeutics

$46.68 /

+1.76 (+3.92%)

Axsome Therapeutics,…

Axsome Therapeutics, announced that, following a Type A meeting with the U.S. Food and Drug Administration, it intends to resubmit its New Drug Application for AXS-07 for the acute treatment of migraine in the third quarter of 2023. The purpose of the Type A meeting was to obtain the FDA's feedback and agreement on the Company's plan to address the issues raised in the previously received Complete Response Letter to support a resubmission of the AXS-07 NDA. The issues principally related to chemistry, manufacturing, and controls considerations. Based on the FDA feedback, the Company will include new CMC information, including stability data on newly manufactured commercial scale batches of AXS-07, in its resubmission package. The resubmission package may also include additional clinical pharmacology information. The Company expects the NDA resubmission to be designated as Class 2 which would be subject to a six-month review. No additional clinical efficacy or safety trials have been requested by the FDA for a resubmission of the NDA.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$46.68 /

+1.76 (+3.92%)

AXSM Axsome Therapeutics
$46.68 /

+1.76 (+3.92%)

09/28/22 Mizuho
Mizuho says Biogen data will serve as catalyst for these stocks
09/07/22 Mizuho
Axsome Therapeutics assumed with a Buy at Mizuho
08/23/22 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $180 at H.C. Wainwright
08/22/22 SVB Securities
Axsome Therapeutics price target raised to $75 from $50 at SVB Securities
AXSM Axsome Therapeutics
$46.68 /

+1.76 (+3.92%)

AXSM Axsome Therapeutics
$46.68 /

+1.76 (+3.92%)

AXSM Axsome Therapeutics
$46.68 /

+1.76 (+3.92%)

Wednesday
On The Fly
Which Alzheimer's stock may be next to jump after Biogen's 'clean’ win? » 10:56
09/28/22
09/28
10:56
09/28/22
10:56
CERE

Cerevel Therapeutics

$28.87 /

+1.155 (+4.17%)

, BTAI

BioXcel Therapeutics

$11.70 /

+0.51 (+4.56%)

, AXSM

Axsome Therapeutics

$46.00 /

+1.08 (+2.40%)

, ATHA

Athira Pharma

$3.30 /

+0.365 (+12.44%)

, ALEC

Alector

$9.18 /

+0.68 (+8.00%)

, A

Agilent

$122.79 /

+1.29 (+1.06%)

, ABOS

Acumen

$8.75 /

+4.12 (+88.98%)

, MOR

MorphoSys

$5.33 /

+0.82 (+18.18%)

, LLY

Eli Lilly

$337.55 /

+26.52 (+8.53%)

, PRTA

Prothena

$54.50 /

+23.55 (+76.09%)

, ESALY

Eisai

$39.79 /

-0.03 (-0.08%)

, BIIB

Biogen

$267.72 /

+69.87 (+35.31%)

Eisai (ESALY) and Biogen…

ShowHide Related Items >><<
PRTA Prothena
$54.50 /

+23.55 (+76.09%)

MOR MorphoSys
$5.33 /

+0.82 (+18.18%)

LLY Eli Lilly
$337.55 /

+26.52 (+8.53%)

ESALY Eisai
$39.79 /

-0.03 (-0.08%)

BTAI BioXcel Therapeutics
$11.70 /

+0.51 (+4.56%)

BIIB Biogen
$267.72 /

+69.87 (+35.31%)

AXSM Axsome Therapeutics
$46.00 /

+1.08 (+2.40%)

ATHA Athira Pharma
$3.30 /

+0.365 (+12.44%)

ALEC Alector
$9.18 /

+0.68 (+8.00%)

ABOS Acumen
$8.75 /

+4.12 (+88.98%)

A Agilent
$122.79 /

+1.29 (+1.06%)

CERE Cerevel Therapeutics
$28.87 /

+1.155 (+4.17%)

09/29/22 Cantor Fitzgerald
Cerevel Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/28/22 Mizuho
Mizuho says Biogen data will serve as catalyst for these stocks
09/26/22 Wells Fargo
Cerevel Therapeutics initiated with an Overweight at Wells Fargo
09/12/22 Evercore ISI
Cerevel Therapeutics initiated with an Outperform at Evercore ISI
BTAI BioXcel Therapeutics
$11.70 /

+0.51 (+4.56%)

08/24/22 H.C. Wainwright
BioXcel Therapeutics price target lowered to $85 from $110 at H.C. Wainwright
07/08/22 Canaccord
BioXcel Therapeutics significant room for upside seen, says Canaccord
07/06/22 Mizuho
BioXcel Therapeutics initiated with a Buy at Mizuho
AXSM Axsome Therapeutics
$46.00 /

+1.08 (+2.40%)

09/07/22 Mizuho
Axsome Therapeutics assumed with a Buy at Mizuho
08/23/22 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $180 at H.C. Wainwright
08/22/22 SVB Securities
Axsome Therapeutics price target raised to $75 from $50 at SVB Securities
ATHA Athira Pharma
$3.30 /

+0.365 (+12.44%)

07/06/22 Mizuho
Athira Pharma initiated with a Buy at Mizuho
06/23/22 Jefferies
Athira Pharma downgraded to Hold from Buy at Jefferies
06/23/22 Stifel
Athira Pharma downgraded to Hold from Buy at Stifel
ALEC Alector
$9.18 /

+0.68 (+8.00%)

09/09/22 Morgan Stanley
Alector downgraded to Equal Weight at Morgan Stanley amid wait for more data
09/09/22 Morgan Stanley
Alector downgraded to Equal Weight from Overweight at Morgan Stanley
07/11/22 Citi
Alector price target lowered to $19 from $34 at Citi
A Agilent
$122.79 /

+1.29 (+1.06%)

08/24/22 Credit Suisse
Agilent initiated with an Outperform at Credit Suisse
08/17/22 BofA
Agilent price target raised to $155 from $148 at BofA
08/17/22 Citi
Agilent price target raised to $145 from $140 at Citi
08/17/22 Baird
Agilent price target raised to $160 from $155 at Baird
ABOS Acumen
$8.75 /

+4.12 (+88.98%)

09/28/22 Stifel
Lecanemab success has 'bullish readthrough' for Acumen, says Stifel
07/15/22 BTIG
Acumen initiated with a Buy at BTIG
06/30/22 H.C. Wainwright
Acumen initiated with a Buy at H.C. Wainwright
03/29/22 Credit Suisse
Acumen price target lowered to $17 from $26 at Credit Suisse
MOR MorphoSys
$5.33 /

+0.82 (+18.18%)

09/06/22 Morgan Stanley
Biogen named a 'Catalyst Driven Idea' at Morgan Stanley
08/10/22 JPMorgan
MorphoSys price target lowered to EUR 32.50 from EUR 34 at JPMorgan
07/29/22 Morgan Stanley
MorphoSys price target raised to EUR 28 from EUR 26 at Morgan Stanley
06/24/22 Morgan Stanley
MorphoSys price target lowered to EUR 26 from EUR 37 at Morgan Stanley
LLY Eli Lilly
$337.55 /

+26.52 (+8.53%)

09/28/22 Morgan Stanley
Eli Lilly likely to trade up 5%-10% on Biogen success, says Morgan Stanley
09/28/22 Cantor Fitzgerald
Lilly shares could move higher on Biogen trial results, says Cantor Fitzgerald
09/22/22 UBS
UBS upgrades Eli Lilly to Buy, says most attractive in big pharma
09/14/22 Piper Sandler
Piper 'surprised' by negative Altimmune reaction after pemvidutide's 'big win'
PRTA Prothena
$54.50 /

+23.55 (+76.09%)

09/28/22 BofA
Prothena upgraded at BofA as Biogen data seen strengthening amyloid thesis
09/28/22 RBC Capital
Prothena price target raised to $52 from $45 at RBC Capital
09/28/22 BofA
Prothena upgraded to Buy from Neutral at BofA
09/28/22 JMP Securities
Prothena price target raised to $81 from $50 at JMP Securities
ESALY Eisai
$39.79 /

-0.03 (-0.08%)

09/28/22 Morgan Stanley
Eisai upgraded to Equal Weight at Morgan Stanley after lecanemab success
09/28/22 Morgan Stanley
Eisai upgraded to Equal Weight from Underweight at Morgan Stanley
BIIB Biogen
$267.72 /

+69.87 (+35.31%)

09/28/22 BTIG
Applied Genetic downgraded to Neutral from Buy at BTIG
09/28/22 Needham
Path for Biogen's lecanemab to be 'multi-step' process, says Needham
PRTA Prothena
$54.50 /

+23.55 (+76.09%)

LLY Eli Lilly
$337.55 /

+26.52 (+8.53%)

CERE Cerevel Therapeutics
$28.87 /

+1.155 (+4.17%)

BTAI BioXcel Therapeutics
$11.70 /

+0.51 (+4.56%)

BIIB Biogen
$267.72 /

+69.87 (+35.31%)

AXSM Axsome Therapeutics
$46.00 /

+1.08 (+2.40%)

ATHA Athira Pharma
$3.30 /

+0.365 (+12.44%)

ALEC Alector
$9.18 /

+0.68 (+8.00%)

ABOS Acumen
$8.75 /

+4.12 (+88.98%)

A Agilent
$122.79 /

+1.29 (+1.06%)

  • 12
    Aug
LLY Eli Lilly
$337.55 /

+26.52 (+8.53%)

MOR MorphoSys
$5.33 /

+0.82 (+18.18%)

LLY Eli Lilly
$337.55 /

+26.52 (+8.53%)

ESALY Eisai
$39.79 /

-0.03 (-0.08%)

CERE Cerevel Therapeutics
$28.87 /

+1.155 (+4.17%)

BTAI BioXcel Therapeutics
$11.70 /

+0.51 (+4.56%)

BIIB Biogen
$267.72 /

+69.87 (+35.31%)

AXSM Axsome Therapeutics
$46.00 /

+1.08 (+2.40%)

ATHA Athira Pharma
$3.30 /

+0.365 (+12.44%)

A Agilent
$122.79 /

+1.29 (+1.06%)

LLY Eli Lilly
$337.55 /

+26.52 (+8.53%)

BIIB Biogen
$267.72 /

+69.87 (+35.31%)

AXSM Axsome Therapeutics
$46.00 /

+1.08 (+2.40%)

ATHA Athira Pharma
$3.30 /

+0.365 (+12.44%)

A Agilent
$122.79 /

+1.29 (+1.06%)

Recommendations
Mizuho says Biogen data will serve as catalyst for these stocks » 07:12
09/28/22
09/28
07:12
09/28/22
07:12
ALEC

Alector

$8.49 /

+0.26 (+3.16%)

, BIIB

Biogen

$197.75 /

+1.985 (+1.01%)

, ATHA

Athira Pharma

$2.93 /

-0.07 (-2.33%)

, AXSM

Axsome Therapeutics

$44.97 /

-0.385 (-0.85%)

, BTAI

BioXcel Therapeutics

$11.19 /

-0.115 (-1.02%)

, CERE

Cerevel Therapeutics

$27.71 /

+0.89 (+3.32%)

Mizuho analyst Graig…

Mizuho analyst Graig Suvannavejh believes Biogen's (BIIB) positive Phase 3 data for lecanemab will serve as an overall catalyst for companies working in the Alzheimer's space. The Phase 3 data for lecanemab "appear to be quite robust" and are likely to support an FDA approval, Suvannavejh tells investors in a research note. That said, given the effect size of 0.45, clinical meaningfulness "could be called into question," says the analyst. He views the Phase 3 data as a "significant positive" for companies not only working on Alzheimer's, but also the neurodegenerative disease space, "where there remains a very high unmet medical need." The companies that could stand to most directly benefit from a stock perspective include Alector (ALEC), Athira Pharma (ATHA), Axsome Therapeutics (AXSM), BioXcel Therapeutics (BTAI) and Cerevel Therapeutics (CERE).

ShowHide Related Items >><<
BTAI BioXcel Therapeutics
$11.19 /

-0.115 (-1.02%)

BIIB Biogen
$197.75 /

+1.985 (+1.01%)

AXSM Axsome Therapeutics
$44.97 /

-0.385 (-0.85%)

ATHA Athira Pharma
$2.93 /

-0.07 (-2.33%)

ALEC Alector
$8.49 /

+0.26 (+3.16%)

ALEC Alector
$8.49 /

+0.26 (+3.16%)

09/09/22 Morgan Stanley
Alector downgraded to Equal Weight at Morgan Stanley amid wait for more data
09/09/22 Morgan Stanley
Alector downgraded to Equal Weight from Overweight at Morgan Stanley
07/11/22 Citi
Alector price target lowered to $19 from $34 at Citi
07/06/22 Mizuho
Alector initiated with a Buy at Mizuho
BIIB Biogen
$197.75 /

+1.985 (+1.01%)

09/28/22 Morgan Stanley
Alzheimer's trial success 'a major positive' for Biogen, says Morgan Stanley
09/28/22 UBS
Biogen lecanemab data is 'major development' in Alzheimer's disease, says UBS
09/28/22 Mizuho
Biogen upgraded to Buy from Neutral at Mizuho
09/28/22 Baird
Biogen upgraded to Outperform from Neutral at Baird
ATHA Athira Pharma
$2.93 /

-0.07 (-2.33%)

07/06/22 Mizuho
Athira Pharma initiated with a Buy at Mizuho
06/23/22 Jefferies
Athira Pharma downgraded to Hold from Buy at Jefferies
06/23/22 Stifel
Athira Pharma downgraded to Hold from Buy at Stifel
06/23/22 JMP Securities
Athira Pharma downgraded to Market Perform from Outperform at JMP Securities
AXSM Axsome Therapeutics
$44.97 /

-0.385 (-0.85%)

09/07/22 Mizuho
Axsome Therapeutics assumed with a Buy at Mizuho
08/23/22 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $180 at H.C. Wainwright
08/22/22 SVB Securities
Axsome Therapeutics price target raised to $75 from $50 at SVB Securities
08/19/22 Truist
Axsome Therapeutics price target raised to $150 from $100 at Truist
BTAI BioXcel Therapeutics
$11.19 /

-0.115 (-1.02%)

08/24/22 H.C. Wainwright
BioXcel Therapeutics price target lowered to $85 from $110 at H.C. Wainwright
07/08/22 Canaccord
BioXcel Therapeutics significant room for upside seen, says Canaccord
07/06/22 Mizuho
BioXcel Therapeutics initiated with a Buy at Mizuho
05/23/22 H.C. Wainwright
BioXcel Therapeutics price target lowered to $110 from $134 at H.C. Wainwright
CERE Cerevel Therapeutics
$27.71 /

+0.89 (+3.32%)

09/26/22 Wells Fargo
Cerevel Therapeutics initiated with an Overweight at Wells Fargo
09/12/22 Evercore ISI
Cerevel Therapeutics initiated with an Outperform at Evercore ISI
08/23/22 Mizuho
Cerevel Therapeutics price target raised to $32 from $27 at Mizuho
08/08/22 Stifel
Cerevel Therapeutics price target raised to $54 from $50 at Stifel
CERE Cerevel Therapeutics
$27.71 /

+0.89 (+3.32%)

BTAI BioXcel Therapeutics
$11.19 /

-0.115 (-1.02%)

BIIB Biogen
$197.75 /

+1.985 (+1.01%)

AXSM Axsome Therapeutics
$44.97 /

-0.385 (-0.85%)

ATHA Athira Pharma
$2.93 /

-0.07 (-2.33%)

ALEC Alector
$8.49 /

+0.26 (+3.16%)

  • 12
    Aug
CERE Cerevel Therapeutics
$27.71 /

+0.89 (+3.32%)

BTAI BioXcel Therapeutics
$11.19 /

-0.115 (-1.02%)

BIIB Biogen
$197.75 /

+1.985 (+1.01%)

AXSM Axsome Therapeutics
$44.97 /

-0.385 (-0.85%)

ATHA Athira Pharma
$2.93 /

-0.07 (-2.33%)

BIIB Biogen
$197.75 /

+1.985 (+1.01%)

AXSM Axsome Therapeutics
$44.97 /

-0.385 (-0.85%)

ATHA Athira Pharma
$2.93 /

-0.07 (-2.33%)

Over a week ago
Options
Axsome Therapeutics call volume above normal and directionally bullish » 11:45
09/09/22
09/09
11:45
09/09/22
11:45
AXSM

Axsome Therapeutics

$62.31 /

+1.12 (+1.83%)

Bullish option flow…

Bullish option flow detected in Axsome Therapeutics with 3,686 calls trading, 1.3x expected, and implied vol increasing almost 5 points to 78.21%. Oct-22 80 calls and Sep-22 62.5 calls are the most active options, with total volume in those strikes near 2,800 contracts. The Put/Call Ratio is 0.07. Earnings are expected on November 7th.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$62.31 /

+1.12 (+1.83%)

AXSM Axsome Therapeutics
$62.31 /

+1.12 (+1.83%)

09/07/22 Mizuho
Axsome Therapeutics assumed with a Buy at Mizuho
08/23/22 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $180 at H.C. Wainwright
08/22/22 SVB Securities
Axsome Therapeutics price target raised to $75 from $50 at SVB Securities
08/19/22 Truist
Axsome Therapeutics price target raised to $150 from $100 at Truist
AXSM Axsome Therapeutics
$62.31 /

+1.12 (+1.83%)

AXSM Axsome Therapeutics
$62.31 /

+1.12 (+1.83%)

AXSM Axsome Therapeutics
$62.31 /

+1.12 (+1.83%)

Hot Stocks
Axsome Therapeutics begins Phase 3 trial of AXS-05 in Alzheimer's Agitation » 07:04
09/08/22
09/08
07:04
09/08/22
07:04
AXSM

Axsome Therapeutics

$61.38 /

+0.8 (+1.32%)

Axsome Therapeutics has…

Axsome Therapeutics has enrolled the first patient in the ADVANCE-2 trial of AXS-05, an investigational treatment for Alzheimer's disease - AD - agitation. ADVANCE-2 - Addressing Dementia via Agitation-Centered Evaluation-2 - is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, trial to assess the efficacy and safety of AXS-05 for the treatment of agitation associated with AD. The primary efficacy measure is the Cohen-Mansfield Agitation Inventory. AXS-05 has been granted FDA Breakthrough Therapy designation for the treatment of Alzheimer's disease agitation.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$61.38 /

+0.8 (+1.32%)

AXSM Axsome Therapeutics
$61.38 /

+0.8 (+1.32%)

09/07/22 Mizuho
Axsome Therapeutics assumed with a Buy at Mizuho
08/23/22 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $180 at H.C. Wainwright
08/22/22 SVB Securities
Axsome Therapeutics price target raised to $75 from $50 at SVB Securities
08/19/22 Truist
Axsome Therapeutics price target raised to $150 from $100 at Truist
AXSM Axsome Therapeutics
$61.38 /

+0.8 (+1.32%)

AXSM Axsome Therapeutics
$61.38 /

+0.8 (+1.32%)

AXSM Axsome Therapeutics
$61.38 /

+0.8 (+1.32%)

Hot Stocks
Axsome Therapeutics announces publication of post-hoc analysis of Sunosi » 07:18
09/07/22
09/07
07:18
09/07/22
07:18
AXSM

Axsome Therapeutics

$60.80 /

-2.25 (-3.57%)

Axsome Therapeutics…

Axsome Therapeutics announced the publication of a post-hoc analysis comparing the effects of Sunosion excessive daytime sleepiness in patients with and without a history of depression. Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea. This secondary analysis included data from two 12-week, randomized, double-blind, placebo-controlled trials in adult patients with EDS associated with narcolepsy or OSA. The analysis showed that treatment with Sunosi improved EDS symptoms both in patients with and without a clinical history of depression, compared to placebo. The results also confirmed earlier findings of a high prevalence of a history of depression in participants with narcolepsy or OSA, and suggest that increased awareness of this association may have clinical significance. Common treatment-emergent adverse events were also similar in those with and without a history of depression.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$60.80 /

-2.25 (-3.57%)

AXSM Axsome Therapeutics
$60.80 /

-2.25 (-3.57%)

09/07/22 Mizuho
Axsome Therapeutics assumed with a Buy at Mizuho
08/23/22 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $180 at H.C. Wainwright
08/22/22 SVB Securities
Axsome Therapeutics price target raised to $75 from $50 at SVB Securities
08/19/22 Truist
Axsome Therapeutics price target raised to $150 from $100 at Truist
AXSM Axsome Therapeutics
$60.80 /

-2.25 (-3.57%)

AXSM Axsome Therapeutics
$60.80 /

-2.25 (-3.57%)

AXSM Axsome Therapeutics
$60.80 /

-2.25 (-3.57%)

Initiation
Axsome Therapeutics assumed with a Buy at Mizuho » 06:41
09/07/22
09/07
06:41
09/07/22
06:41
AXSM

Axsome Therapeutics

$60.80 /

-2.25 (-3.57%)

Mizuho analyst Graig…

Mizuho analyst Graig Suvannavejh assumed coverage of Axsome Therapeutics with a Buy rating and price target of $76, up from $49. The company is developing a portfolio of assets targeting disorders of the central nervous system, addressing large markets with unmet medical need, Suvannavejh tells investors in a research note. He sees "modest novelty" in Axsome's candidates, while noting the markets they address feature meaningful branded and generic competition.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$60.80 /

-2.25 (-3.57%)

AXSM Axsome Therapeutics
$60.80 /

-2.25 (-3.57%)

08/23/22 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $180 at H.C. Wainwright
08/22/22 SVB Securities
Axsome Therapeutics price target raised to $75 from $50 at SVB Securities
08/19/22 Truist
Axsome Therapeutics price target raised to $150 from $100 at Truist
08/10/22 Cantor Fitzgerald
Axsome Therapeutics price target lowered to $54 from $64 at Cantor Fitzgerald
AXSM Axsome Therapeutics
$60.80 /

-2.25 (-3.57%)

AXSM Axsome Therapeutics
$60.80 /

-2.25 (-3.57%)

AXSM Axsome Therapeutics
$60.80 /

-2.25 (-3.57%)

Over a month ago
Hot Stocks
Axsome enrolls 1st patient in EMERGE trial of AXS-07 for migraine treatment » 07:06
09/01/22
09/01
07:06
09/01/22
07:06
AXSM

Axsome Therapeutics

$63.75 /

+2.48 (+4.05%)

Axsome Therapeutics,…

Axsome Therapeutics, announced that it has enrolled the first patient in the EMERGE trial of AXS-07 for the acute treatment of migraine. EMERGE is a Phase 3, open-label, multicenter trial to assess the efficacy and safety of AXS-07 in the acute treatment of migraine in patients with a prior inadequate response to an oral Calcitonin Gene-Related Peptide, CGRP, inhibitor. Approximately 100 patients experiencing migraine attacks will be treated with AXS-07 for up to eight weeks, following an inadequate response to prior treatment with an oral CGRP inhibitor. The two co-primary endpoints will be pain relief and absence of the most bothersome symptom two hours after dosing. The study is being conducted to further elucidate the clinical profile of AXS-07 and is not a regulatory requirement.

ShowHide Related Items >><<
AXSM Axsome Therapeutics
$63.75 /

+2.48 (+4.05%)

AXSM Axsome Therapeutics
$63.75 /

+2.48 (+4.05%)

08/23/22 H.C. Wainwright
Axsome Therapeutics price target raised to $210 from $180 at H.C. Wainwright
08/22/22 SVB Securities
Axsome Therapeutics price target raised to $75 from $50 at SVB Securities
08/19/22 Truist
Axsome Therapeutics price target raised to $150 from $100 at Truist
08/10/22 Cantor Fitzgerald
Axsome Therapeutics price target lowered to $54 from $64 at Cantor Fitzgerald
AXSM Axsome Therapeutics
$63.75 /

+2.48 (+4.05%)

AXSM Axsome Therapeutics
$63.75 /

+2.48 (+4.05%)

AXSM Axsome Therapeutics
$63.75 /

+2.48 (+4.05%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.